One68 Global Capital’s Acurx Pharmaceuticals ACXP Stock Holding History

One68 Global Capital’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-652	Closed	-$34.6K	–	3
2023 Q2	$34.6K	Buy	+652	New	+$38.8K	0.21%	22

Other funds holding ACXP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

One68 Global Capital's ACXP Position: Q3 2023 in Review

One68 Global Capital sold out of Acurx Pharmaceuticals (ACXP) in Q3 2023, closing a stake of 652 shares — an estimated $34.6K sold.

One68 Global Capital first reported a position in ACXP in Q2 2023 and held it in 1 quarter. The position peaked at $34.6K in Q2 2023. 18 funds tracked by Wall St. Rank hold ACXP as of Q3 2023.

One68 Global Capital reported no remaining Acurx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
One68 Global Capital sold 652 Acurx Pharmaceuticals shares in Q3 2023, an estimated $34.6K.
One68 Global Capital first reported a position in Acurx Pharmaceuticals in Q2 2023 and held it in 1 quarter.
One68 Global Capital's Acurx Pharmaceuticals position peaked at $34.6K in Q2 2023.
18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2023.

Based on One68 Global Capital's 13F filing for Q3 2023.